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butions (e.g. hospital stays). Therefore, estimates of uncertainty
must be factored into economic facets of HTAs.
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Industry, too, faces challenges as we enter the era of molecularly
targeted therapy. Investment in the research and development
can be significant, but a targeted therapy may be appropriate
for only a subset of patients who have the correct molecular tar-
get. Screening would eliminate patients for whom the treatment
would not be effective. As such, the development costs may
increase but the potential patient population may decrease.
Therefore, incentives need to be in place to ensure that manufac-
turers can realise a return on their investment.
Molecularly targeted therapy appears to offer an attractive
value proposition; however, this can only be realised if industrial
incentives are aligned with health care incentives. Introducing
these therapies into practice presents some challenges. ‘Both
strong intellectual property protections and value-based, flexible
pricing systems will be important in making personalised medi-
cine a reality.’2
Health care expenditures, both in absolute terms and as a per-
centage of gross domestic product (GDP) are growing around the
world. Innovative drugs are becoming more difficult to find, and
more expensive to develop. Together these present significant
challenges to both Payers and the Pharmaceutical Industry.
The challenge is developing successful next-generation oncol-
ogy drugs within this environment. Success may be defined in
several different ways. Success, to the patient, means access to
a treatment that works. For the physician, it means using the
right drugs in the right patients at the right time. Success, as
defined by payers, connotes affordability and value for monies
spent. Pharmaceutical companies seek success in the form of
payback on their investment in research and development.
According to the traditional view of drug development and
licensure, the product has three hurdles to negotiate: safety, effi-
cacy and quality. In reality, however, at least three additional hur-
dles must be surmounted: national pricing and reimbursement,
local/regional market access and health technology assessment
(HTA). These last three include financial pressures in their evalu-
ation. There is one additional challenge that must be considered
at the outset of the development process – the need to measure
value. To achieve success, pharmaceutical companies have to
demonstrate that a product will deliver value (to the patient,
and to the health economy) and net a return on their investment.
The highest hurdle is HTA, which has been defined as ‘a mul-
tidisciplinary process that summarises information about the
medical, social, economic and ethical issues related to the use
of a health technology in a systematic, transparent, unbiased,
robust manner. Its aim is to inform the formulation of safe, effec-
tive, health policies that are patient focused and seek to achieve
best value.’3 Nearly 50% of licensed therapies fail to fully sur-
mount the HTA hurdle in some way.
Not all drugs need to be subjected to the same levels of rigorous
evaluation. The amount and quality of evidence required for licen-
sure varies, and evidence required to support drug pricing and
market access follows a parallel track. For example, therapies that
are initially innovative (with price based on the value delivered)
are eventually joined in the market by other drugs that are thera-
peutically similar, resulting in cluster-based or reference pricing.
Payer–Industry partnerships could be an attractive, and poten-
tially successful approach in the future, as well (Fig. 1). Much
might be gained by leveraging complementary skills sets and
through access to, and analysis of, comprehensive (real-world)
treatment and outcomes data. Ultimately, payers and pharma-
ceutical firms are working for the same person – the patient.
SURMOUNTING THE HTA HURDLE: HTA poses a number of
questions regarding new therapies. First, how is the new treat-
ment or technology to be used? This line of questioning should
include the potential role or position of the therapy, the patients
most likely to benefit from it, when in the disease course should it
be used, and for how long. In addition to clinical-efficacy and –
effectiveness, questions of cost effectiveness and resource utilisa-
tion must be asked: How much does the therapy cost? Is it afford-
able? Does it represent acceptable ‘value for money’? (i.e. is it cost
effective?) What is the best way to allocate scarce resources? Eval-
uation of cost effectiveness is often one of the most important
components of HTA.
Key concepts often addressed are affordability, value for
money, and willingness to pay. Implicit are issues of rational
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Fig. 1 – Payer–industry partnership: an integrated approach.
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rationing and rational health care resource allocation. Industry
does not like the notion of rationing, but it supports identifying
the best use of medicines in terms of the most appropriate
patients for the treatment and the most appropriate time in their
disease progression or treatment. There is a significant role for
BDA in working toward the aim of using biologics and biomarkers
in identifying most appropriate target populations and the opti-
mal time for treatment. Another key concept in HTA is reducing
uncertainty, which decreases as the number of clinical studies
evaluating safety and efficacy increases. HTA has a significant
impact on data requirements. Meeting the HTA hurdle requires
strong epidemiological evidence (i.e. the potential number of suit-
able patients), as well as an evidence-based position for the new
agent in therapy or clinical guidelines. Ideally data are also neces-
sary that identify the subpopulations that receive the greatest
clinical benefit. Investigation of the agent must be based on
meaningful endpoints and economic models must be transpar-
ent. Clinical trials must demonstrate its clinical efficacy and
safety. Real-world studies must identify its clinical effectiveness.
Finally, analysis of economic effectiveness of the agent must
demonstrate its budget impact, cost effectiveness, cost utility
and address equitable use. All supporting studies must include
an indication of evidence quality.
A ROLE FOR BIOMARKERS AND SURROGATE ENDPOINTS IN
HTA: How do clinical trial endpoints based on biomarkers figure
into the development and licensure scheme? Biomarkers are sur-
rogate endpoints that have substantial value in both clinical and
HTA evaluations of new products. Biomarkers can be used to
identify likely responding patients who have an abnormal condi-
tion prior to treatment initiation. They can also be used to assess
the extent of disease, monitor the safety of an intervention, and
evaluate the desired response.1
There are, however, some problems associated with reliance
on surrogate rather than clinical endpoints in trials of antican-
cer agents. First, one must understand under what circum-
stances a surrogate endpoint provides both a qualitative and
quantitative prediction of the clinical endpoint. Second, surro-
gate endpoints provide little or no information about the risk–
benefit profile of the product and scant quantitative evidence
of the magnitude of any effects on utility. For example, demon-
strating an anti-tumour agent’s significant effect on complete or
partial response rates may have little relationship to its effect on
either longevity or quality of life. The ultimate goal is to work
toward patient benefit and measuring outcomes that are mean-
ingful to, and valued by, the patient. Ideally the focus should
evolve from patient reported outcomes to patient relevant
outcomes.
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Demands are increasing on health care systems as the population
ages and competition heats up among numerous branches. What
data should serve as the basis for difficult decisions, and who
should make them? Various financial barometers signal that bur-
geoning needs and shrinking resources will lead to scarcity (or
perhaps, a perception of scarcity), and reimbursement is a central
part of scarcity steering. To balance needs with available
resources, wemust establish priorities based on state, association
and individual regulations.
Disease and scarcity are considered by people today to be
unconquerable and omnipresent. The greater the knowledge peo-
ple have of disease and its panoply of treatments, the greater is
their awareness of the gap between demand and resources. Inter-
estingly, the more society spends for disease management and
meeting health-care needs, the larger the scarcity appears to be.
Stated otherwise, being on the highest-ever level of material sup-
ply and per capita health-care spending for all ages in Europe, the
topic of scarcity is being discussed more heatedly than at any
other time.
For conventional cancer treatments for which response to
treatment depends on the duration of treatment, the greatest
value likely occurs near the beginning of treatment and decreases
over time. The interest of payers is in reducing cost, and the inter-
est of doctors and patients is in maximising treatment. Maximal
medical care, of course, has higher costs. Optimal treatment, in
an economic sense, occurs where the cost curve intersects the
curve representing decreasing medical benefits over time. Payers,
patients and doctors negotiate and compromise to arrive at the
point of economically optimised medical care.
Predictive markers must be developed for molecularly tar-
geted therapies to improve the benefit–cost relationship by only
treating patients with a high expectation of response. For regis-
tration or licensure of new products, alternatives to randomised
trials should be considered. Indirect comparisons might help
facilitate patient access to new medicines. Also, it is important
to keep in mind that molecularly targeted therapies mostly
involve small populations. Randomised trials require a great deal
of time, during which therapeutic options might change, thereby
compromising the value of the trial’s findings.
Academia, industry, regulators as well as patient advocacy
groups and economists will have to act in concert, and scientific
associations, suchas the BDAwill have to take active roles. Of para-
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